Agile Therapeutics, Inc. (AGRX) News
Filter AGRX News Items
AGRX News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
AGRX News Highlights
- AGRX's 30 day story count now stands at 5.
- Over the past 28 days, the trend for AGRX's stories per day has been choppy and unclear. It has oscillated between 1 and 1.
- NOTE are the most mentioned tickers in articles about AGRX.
Latest AGRX News From Around the Web
Below are the latest news stories about AGILE THERAPEUTICS INC that investors may wish to consider to help them evaluate AGRX as an investment opportunity.
Agile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2022 Earnings Call TranscriptAgile Therapeutics, Inc. (NASDAQ:AGRX) Q4 2022 Earnings Call Transcript March 24, 2023 Operator: Good afternoon and welcome to the Agile Therapeutics Fourth Quarter and Full Year 2022 Financial Results Conference Call. Please note, today’s event is being recorded. I would now like to turn the conference over to Matt Riley, Head of Investor Relations. Matt […] |
Q4 2022 Agile Therapeutics Inc Earnings CallQ4 2022 Agile Therapeutics Inc Earnings Call |
Agile Therapeutics Reports Fourth Quarter & Full Year 2022 Financial Results and Provides Corporate UpdateFourth Quarter 2022 Net Revenue Increased 33% from Third Quarter 2022 While GAAP Quarter-Over-Quarter OPEX Decreased 55% and Non-GAAP OPEX Remained Unchanged Twirla Demand and Factory Sales Up 25% and 30% Respectively in Fourth Quarter 2022 vs Third Quarter 2022 Company Reaffirms Expected Full Year 2023 Net Revenue in Range of $25-$30 Million Management to Host Conference Call Today, Wednesday, March 22, 2023 at 4:30 p.m. ET PRINCETON, N.J., March 22, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, |
Agile Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on Wednesday, March 22, 2023Live Conference Call and Webcast at 4:30 p.m. ETPRINCETON, N.J., March 21, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX), a women's healthcare company, today announced it will report fourth quarter and full year 2022 financial results after the market close on Wednesday, March 22, 2023. Following the release, the Company will host a live conference call and webcast at 4:30 p.m. ET to discuss the Company’s financial results and provide a business update. EventAgile Therapeutics |
Agile Therapeutics Granted 180-Day Extension by Nasdaq to Meet the Minimum Bid Price RequirementPRINCETON, N.J., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc. (Nasdaq: AGRX) (“Agile” or the “Company”), a women's healthcare company, today announced that it has received written notification from the Listing Qualifications Department of the Nasdaq Stock Market LLC (“Nasdaq”) granting the Company’s request for a 180-day extension to regain compliance under Nasdaq Listing Rule 5550(a)(2). The Company now has until August 14, 2023 to meet the requirement (the “Compliance Date”). The |
Are Medical Stocks Lagging Ardelyx (ARDX) This Year?Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year. |
Corium Pharma Solutions Names Ernie De Paolantonio as Chief Financial OfficerCorium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Ernie De Paolantonio as Chief Financial Officer. This announcement follows the recent appointments of several industry veterans, Mark Sirgo as Chief Executive Officer, Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technolo |
Corium Pharma Solutions Names Two Industry Veterans to its Executive TeamCorium Pharma Solutions, Inc. (CPSI), a leading, full-service contract development and manufacturing organization specializing in novel drug delivery technologies for prescription drug and consumer products including transdermal modalities, has named Kevin Ostrander as Chief Business Officer and Dr. Niraj Vasisht as Chief Technology Officer. These appointments, including CPSI's recent announcement that Mark Sirgo had been named Chief Executive Officer, further strengthen CPSI's executive team an |
Is Ardelyx (ARDX) Stock Outpacing Its Medical Peers This Year?Here is how Ardelyx (ARDX) and Agile Therapeutics (AGRX) have performed compared to their sector so far this year. |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to start the day with a breakdown of the biggest pre-market stock movers traders need to know about on Thursday! |